Autolus Therapeutics plc AUTL
Nov 11, 2026, 1:29 PM EST
- YTD
- -36.18%
- 1 year
- -15.33%
- Market cap
- 339.36M
- Revenue (ttm)
- 10.09M
- EPS (ttm)
- -1.06
- Shares out
- 266.12M
- Forward P/E
- -3.08
- YTD return
- -36.18%
- 1-year return
- -15.33%
- Volume
- 3.00M
- Avg volume
- 2.14M
- Open
- 1.32
- Previous close
- 1.32
- Day's range
- 1.20 – 1.33
- 52-week range
- 1.12 – 2.58
- Analysts
- Strong Buy
- Price target
- 10.45 (+722.8%)
- Earnings date
- Aug 8, 2024
5D -0.07 (-5.22%)
Key statistics
- Enterprise value
- 253.44M
- PEG ratio
- 0.00
- Price / sales
- 59.34
- Price / book
- 1.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -171.18M
- Total cash
- 657.07M
- Total debt
- 301.17M
- Return on equity
- -82.20%
- Short % of float
- 3.19%
- 50-day average
- 3.39
- 200-day average
- 4.08
Analyst view
Consensus: strong buy
- Target (low)
- 7.60
- Target (mean)
- 10.45
- Target (high)
- 13.00
- Strong buy2
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.22411.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.21 | -0.31 | -0.10 | -47.62% |
| Aug 8, 2024 | Jun 1, 2024 | -0.19 | -0.22 | -0.03 | -15.79% |
| Aug 8, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| May 17, 2024 | Mar 1, 2024 | -0.10 | -0.24 | -0.14 | -140.00% |
| May 17, 2024 | Mar 1, 2024 | -0.10 | — | — | — |
| Mar 14, 2024 | Dec 1, 2023 | -0.26 | -0.44 | -0.18 | -69.23% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | Needham | reit | Buy | Buy |
| Dec 5, 2024 | Needham | reit | Buy | Buy |
| Nov 18, 2024 | Goldman Sachs | up | Neutral | Buy |
| Nov 15, 2024 | Redburn Atlantic | up | Neutral | Buy |
| Nov 13, 2024 | Needham | reit | Buy | Buy |
| Nov 12, 2024 | Needham | main | Buy | Buy |
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- autolus.com
News
Autolus Therapeutics Presents Longer-Term Follow Up Data From Ongoing CARLYSLE Phase 1 Trial; Data Show Clinically Significant Improvements In SLEDAI-2K Scores And Achievement Of DORIS In Most Patients Despite Severe Disease Activity At Baseline 
Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 
Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript 
Autolus Therapeutics Q3 Earnings Call Highlights 
Autolus Therapeutics Q3 2026 Earnings Call Transcript 
Autolus Therapeutics FY2026 AUCATZYL net product revenue expected to be more than $150.000M 
Autolus Therapeutics Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $41.238M Beat $39.537M Estimate 
Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates 
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference - Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15
Your note
Sign in to keep a note on AUTL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wellington Management Group, LLP | 9.10% | 24,220,226 | 54.50M | Sep 29, 2024 |
| Blackstone Inc | 7.70% | 20,485,611 | 46.09M | Sep 29, 2024 |
| Syncona Portfolio Ltd | 6.97% | 18,554,624 | 41.75M | Sep 29, 2024 |
| FMR, LLC | 6.68% | 17,773,873 | 39.99M | Sep 29, 2024 |
| Deep Track Capital, Lp | 5.74% | 15,272,172 | 34.36M | Sep 29, 2024 |
| Avoro Capital Advisors LLC | 4.64% | 12,345,678 | 27.78M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Specialized-Health Care Fund | 7.10% | 18,895,107 | 42.51M | Jul 30, 2024 |
| Fidelity Small Cap Growth Fund | 0.97% | 2,571,371 | 5.79M | Aug 30, 2024 |
| Fidelity Series Small Cap Opportunities Fund | 0.94% | 2,513,475 | 5.66M | Aug 30, 2024 |
| Price (T.Rowe) New Horizons Fund | 0.85% | 2,268,455 | 5.10M | Sep 29, 2024 |
| Fidelity Advisor Biotechnology Fund | 0.73% | 1,940,346 | 4.37M | Oct 30, 2024 |
| Fidelity Stock Selector Small Cap Fund | 0.64% | 1,706,679 | 3.84M | Aug 30, 2024 |